PLYMOUTH MEETING, Pa., Oct. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2023 financial results on Tuesday, October 31, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on October 31, 2023, at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial (800) 245-3047 (domestic) or +1 (203) 518-9765 (international), and reference passcode HRMYQ323. It is recommended that you dial in at least 10 minutes prior to the call.
The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
This email address is being protected from spambots. You need JavaScript enabled to view it.
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$34.33 |
| Daily Change: | 0.02 0.06 |
| Daily Volume: | 557,432 |
| Market Cap: | US$1.970B |
June 05, 2025 April 08, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
